Physician profile
Umer Dasti
NPI 1497916845
$8,053.05
in general payments reported to CMS, 2019-2025
12 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $37.80 · 2021: $70.98 · 2022: $2,370 · 2023: $1,399 · 2024: $905 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,804 · Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,804.16 |
| Food and Beverage | $1,365.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,133.00 | 2019-2025 | Blueprint Patient Specific Instrumentation, Pangea, Tornier Perform Anatomic Augmented Glenoid |
| Seapearl East, INC | $2,965.30 | 2019-2024 | |
| Arthrex, INC. | $1,565.95 | 2019-2023 | Arthroplasty Implants Anatomic Total Shoulder Eclipse |
| Kerecis Limited | $142.19 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Zimmer Biomet Holdings, INC. | $50.00 | 2022 | |
| Henry Schein, INC. | $40.76 | 2023 | |
| Solventum Corporation | $39.82 | 2025 | Prevena |
| Kci USA, INC. | $26.30 | 2020 | |
| Integra Lifesciences Corporation | $26.21 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $25.71 | 2020-2023 | Caldolor |
| Smith+Nephew, INC. | $23.71 | 2025 | Pico 14 |
| Bioventus LLC | $14.10 | 2024 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Dasti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.